Canada markets closed
  • S&P/TSX

    19,171.66
    -32.04 (-0.17%)
     
  • S&P 500

    4,124.66
    -16.93 (-0.41%)
     
  • DOW

    33,730.89
    +53.62 (+0.16%)
     
  • CAD/USD

    0.7990
    +0.0002 (+0.02%)
     
  • CRUDE OIL

    62.84
    -0.31 (-0.49%)
     
  • BTC-CAD

    78,821.89
    -663.97 (-0.84%)
     
  • CMC Crypto 200

    1,368.33
    -7.45 (-0.54%)
     
  • GOLD FUTURES

    1,736.10
    -0.20 (-0.01%)
     
  • RUSSELL 2000

    2,247.72
    +18.79 (+0.84%)
     
  • 10-Yr Bond

    1.6380
    +0.0150 (+0.92%)
     
  • NASDAQ futures

    13,823.00
    +24.25 (+0.18%)
     
  • VOLATILITY

    16.99
    +0.34 (+2.04%)
     
  • FTSE

    6,939.58
    +49.09 (+0.71%)
     
  • NIKKEI 225

    29,620.99
    +82.29 (+0.28%)
     
  • CAD/EUR

    0.6666
    -0.0007 (-0.10%)
     

G1 Therapeutics to Participate in Two Investor Conferences in March

  • Oops!
    Something went wrong.
    Please try again later.
G1 Therapeutics
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

RESEARCH TRIANGLE PARK, N.C., March 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two investor conferences in March.

Jack Bailey, G1’s Chief Executive Officer, will provide a presentation during the HC Wainwright Global Life Sciences Conference; this presentation will be available starting on March 9, 2021 at 7:00 AM ET. In addition, Mr. Bailey will also participate in a fireside chat during the Roth 33rd Annual Conference on March 17, 2021 at 10:30 AM ET.

These conferences are being held virtually, and webcasts will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com